Charles River Laboratories International, Inc. (CRL): Price and Financial Metrics

Charles River Laboratories International, Inc. (CRL)

Today's Latest Price: $232.83 USD

3.74 (1.63%)

Updated Oct 22 1:49pm

Add CRL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

CRL Stock Summary

  • Charles River Laboratories International Inc's market capitalization of $11,581,570,153 is ahead of 85.75% of US-listed equities.
  • CRL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 316.82 -- higher than 89.07% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Charles River Laboratories International Inc is higher than 78.65% of stocks in our set with a positive cash flow.
  • If you're looking for stocks that are quantitatively similar to Charles River Laboratories International Inc, a group of peers worth examining would be RXN, BFAM, TTEK, ICLR, and CLGX.
  • CRL's SEC filings can be seen here. And to visit Charles River Laboratories International Inc's official web site, go to

CRL Stock Price Chart Interactive Chart >

Price chart for CRL

CRL Price/Volume Stats

Current price $232.83 52-week high $250.29
Prev. close $229.09 52-week low $95.58
Day low $229.49 Volume 132,184
Day high $234.24 Avg. volume 395,070
50-day MA $223.08 Dividend yield N/A
200-day MA $178.27 Market Cap 11.57B

Charles River Laboratories International, Inc. (CRL) Company Bio

Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.

CRL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$232.83$140.51 -40%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Charles River Laboratories International Inc. To summarize, we found that Charles River Laboratories International Inc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Charles River Laboratories International Inc ended up being:

  • Charles River Laboratories International Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 5.92. This coverage rate is greater than that of 66.36% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 8. This value is greater than merely 19.54% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CRL, try GSK, PRGO, ENDP, HZNP, and MD.

CRL Latest News Stream

Event/Time News Detail
Loading, please wait...

CRL Latest Social Stream

Loading social stream, please wait...

View Full CRL Social Stream

Latest CRL News From Around the Web

Below are the latest news stories about Charles River Laboratories International Inc that investors may wish to consider to help them evaluate CRL as an investment opportunity.

Streaming Agreement for up to US$20M Finalised

Comet Resources Ltd (Comet or the Company) (ASX:CRL) is pleased to announce that is has executed binding documents with Raptor Capital International Limited The post Streaming Agreement for up to US$20M Finalised appeared first on Investing News Network .

Investing News Network | September 15, 2020

Charles River Laboratories: Strong Results But Not Out Of The Woods Just Yet

Charles River Laboratories' (CRL) stock has performed well so far in 2020, as CRL shares are outperforming the broader market by ~35 percentage points over the last 8 plus months. Data by YCharts And it helps the bull case that the company's Q2 2020 results were well-received by the market,...

WG Investment Research on Seeking Alpha | August 16, 2020

Should Investors Buy the Dip in Charles River Laboratories (CRL) Stock?

Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for […]

Yahoo | July 31, 2020

COVID-19 Impact & Recovery Analysis | Healthcare Analytical Testing Services Market 2020-2024 | Evolving Opportunities with Almac Group Ltd. and Charles River Laboratories International Inc. | Technavio

The Global Healthcare Analytical Testing Services Market will grow by $ 3.98 bn during 2020-2024

Business Wire | July 29, 2020

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Read More 'CRL' Stories Here

CRL Price Returns

1-mo 7.13%
3-mo 20.74%
6-mo 70.01%
1-year 84.71%
3-year 102.62%
5-year 255.09%
YTD 52.42%
2019 34.97%
2018 3.41%
2017 43.65%
2016 -5.22%
2015 26.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7829 seconds.